- Ensysce Biosciences Inc (ENSC, Financial) has concluded the first part of its key clinical trial for PF614-MPAR, showcasing enhanced safety in opioid use.
- Wall Street predicts substantial potential growth for ENSC, with an average price target suggesting a tenfold increase.
- The stock currently enjoys an "Outperform" rating from analysts, reflecting confidence in its future prospects.
Ensysce Biosciences Inc. (ENSC) recently announced a significant milestone, completing Part 1 of its pivotal clinical trial for PF614-MPAR. This innovative drug is engineered to provide effective severe pain relief while mitigating the risk of opioid overdose. The trial results demonstrated that PF614-MPAR can successfully limit the excessive release of oxycodone, ensuring patient safety without compromising on pain management efficacy.
Wall Street Analysts' Forecast
The outlook for Ensysce Biosciences Inc (ENSC, Financial) appears promising, as reflected in the one-year price targets set by analysts. Currently, the average target price is $46.73, with projections ranging from a high of $75.00 to a low of $18.45. This average target suggests a remarkable potential upside of 1,036.86% from the current share price of $4.11. Investors seeking detailed estimate data can visit the Ensysce Biosciences Inc (ENSC) Forecast page.
Furthermore, Ensysce Biosciences Inc (ENSC, Financial) is receiving favorable sentiment from market analysts, with a consensus recommendation score of 2.0. This positions the stock within the "Outperform" category. The rating scale utilized by brokerage firms ranges from 1 to 5, where 1 indicates a Strong Buy and 5 suggests a Sell. This optimistic rating underscores analysts' confidence in ENSC's future growth and innovation potential.
